Takayoshi Owada

ORCID: 0000-0003-3457-0207
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Inflammatory Myopathies and Dermatomyositis
  • Sarcoidosis and Beryllium Toxicity Research
  • Eosinophilic Disorders and Syndromes
  • Immune Cell Function and Interaction
  • Systemic Sclerosis and Related Diseases
  • Medical Imaging and Pathology Studies
  • T-cell and B-cell Immunology
  • Heterotopic Ossification and Related Conditions
  • Immunodeficiency and Autoimmune Disorders
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Pneumonia and Respiratory Infections
  • Asthma and respiratory diseases
  • Cerebral Venous Sinus Thrombosis
  • Cytokine Signaling Pathways and Interactions
  • Systemic Lupus Erythematosus Research
  • Liver Diseases and Immunity
  • Skin Diseases and Diabetes
  • Muscle and Compartmental Disorders
  • Autoimmune Bullous Skin Diseases
  • Amino Acid Enzymes and Metabolism
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Diabetes and associated disorders
  • Mast cells and histamine
  • NF-κB Signaling Pathways

Dokkyo Medical University
2015-2025

Social Insurance Saitama Chuo Hospital
2021-2025

Dokkyo Medical University Saitama Medical Center
2023-2024

Dokkyo University
2020

Chiba University
2008-2013

Chiba University Hospital
2009-2011

Yokohama Rosai Hospital
2009

We aimed to determine the outcome of combination therapy with tofacitinib (TOF) in a case series refractory rapidly progressive interstitial lung disease (ILD) associated anti-melanoma differentiation-associated 5 gene (MDA5) antibody-positive (Ab+) DM. Patients who had poor prognostic factors and failed respond immunosuppressive were selected for TOF treatment.Five patients anti-MDA5 Ab+ DM-ILD triple high dose glucocorticoids, CSA CYC given additional (10 mg/day). To identify factors, data...

10.1093/rheumatology/key188 article EN Lara D. Veeken 2018-06-20

Abstract Objective B and T lymphocyte attenuator (BTLA), a coreceptor expressed on lymphocytes, was recently described as an inhibitory that negatively regulates activation. The purpose of this study to investigate the role BTLA in regulation immune homeostasis pathogenesis autoimmunity. Methods We examined levels immunoglobulins autoantibodies nuclear antigens activation status cells −/− mice. also histopathologic changes organs Results observed mice gradually developed...

10.1002/art.23674 article EN Arthritis & Rheumatism 2008-07-30

Recent studies have suggested that statins, the inhibitors for 3-hydroxy-3-methyglutaryl (HMG)-CoA reductase in mevalonate pathway, exhibit anti-inflammatory effects. However, immune modulatory effects of statins on differentiation CD4+ T cells and their underlying mechanisms are still largely unknown. To address these issues, we examined effect simvastatin protein farnesylation geranylgeranylation IL-17-producing (Th17 cells) Foxp3+ cells. Simvastatin inhibited Th17 through inhibition...

10.1093/intimm/dxp037 article EN International Immunology 2009-04-20

To evaluate the usefulness of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging in management patients with inflammatory myopathy. We examined whether FDG-PET scanning detects myositis or extramuscular lesions polymyositis (PM) and dermatomyositis (DM).FDG-PET was performed 24 active myopathy (PM, 11; DM, 13). The images were read by radiologists a blinded manner. FDG uptake into muscles judged positive when intensity higher than equal to that liver. As controls,...

10.3899/jrheum.111597 article EN The Journal of Rheumatology 2012-07-01

Although innate immune responses are necessary for the initiation of acquired and subsequent successful elimination pathogens, excessive occasionally result in lethal endotoxic shock accompanied by a cytokine storm. B T lymphocyte attenuator (BTLA), coinhibitory receptor with similarities to cytotoxic T-lymphocyte antigen (CTLA)-4 programmed death (PD)-1, is expressed not only cells but also dendritic (DCs) macrophages (Mϕs). Recently, several studies have reported that BTLA-deficient (BTLA...

10.1073/pnas.1222093110 article EN Proceedings of the National Academy of Sciences 2013-03-11

Journal Article Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis patients with active interstitial pneumonia associated polymyositis/dermatomyositis Get access Satoko Arai, Arai Clinical Immunology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi 321-0293, Japan Search for other works by this author on: Oxford Academic Google Scholar Kazuhiro Kurasawa, Kurasawa Correspondence to: e-mail:...

10.3109/s10165-012-0756-0 article EN Modern Rheumatology 2013-09-01

Inhibitory coreceptors are thought to play important roles in maintaining immunological homeostasis, and a defect the negative signals from inhibitory may lead development of autoimmune diseases. We have recently identified B T lymphocyte attenuator (BTLA), new coreceptor expressed on immune cells, we suggest that BTLA be involved diseases using BTLA-deficient mice. However, role pathogenesis humans remains unknown. We, therefore, examined possible association between rheumatoid arthritis...

10.1155/2011/305656 article EN cc-by Clinical and Developmental Immunology 2011-01-01

Journal Article Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis patients with active interstitial pneumonia associated polymyositis/dermatomyositis Get access Satoko Arai, Arai Clinical Immunology, Dokkyo Medical University, 880 Kita-Kobayashi, Mibu, Tochigi 321-0293, Japan Search for other works by this author on: Oxford Academic Google Scholar Kazuhiro Kurasawa, Kurasawa Correspondence to: e-mail:...

10.1007/s10165-012-0756-0 article EN Modern Rheumatology 2012-09-16

Although B and T lymphocyte attenuator (BTLA) was originally identified as an inhibitory coreceptor selectively expressed on Th1 cells cells, recent studies have revealed that BTLA is a variety of including macrophages, dendritic NK modulates their functions. However, the role in regulation NKT cell function remains unknown. In this study, we found at levels similar to those BTLA-deficient (BTLA(-/-)) produced larger amounts IL-4 IFN-gamma upon alpha-glactosylceramide stimulation compared...

10.4049/jimmunol.0900389 article EN The Journal of Immunology 2009-12-01

MRL/Mp-Fas (lpr) (MRL-lpr) mice develop a systemic autoimmune disease and are considered to be good model for lupus erythematosus in humans. We have recently shown that lacking B T lymphocyte attenuator (BTLA), an inhibitory co-receptor expressed mainly on lymphocytes, 129SvEv background spontaneously lymphocytic infiltration multiple organs hepatitis (AIH)-like disease. In this study, we investigated the role of BTLA pathogenesis diseases MRL-lpr mice. found BTLA-deficient (BTLA−/−)...

10.1093/intimm/dxr017 article EN International Immunology 2011-04-26

To clarify the clinical features of organizing pneumonia (OP) associated with rheumatoid arthritis (RA) and to determine whether development OP is related RA activity.A cross-sectional study was conducted, in which medical records 499 consecutive patients who visited our hospital during one month were reviewed. diagnosed by pathological findings trans-bronchial biopsy or (typical computed tomography findings, no causative agents, good response glucocorticoids, lack antibiotics).Among...

10.3109/14397595.2016.1153217 article EN Modern Rheumatology 2016-02-14

Autoantibody against platelet-derived growth factor receptors (PDGFRs) has been reported in scleroderma (SSc). However, it remains unknown whether anti-PDGFRs antibody exists collagen vascular diseases other than SSc. To answer the question, we developed an ELISA system and examined sera from patients with SLE (n = 75), SSc 31), RA 25) control individuals. We also reviewed medical records to clarify clinical features of anti-PDGFRα antibody. examine functions patients, fibroblasts were...

10.1007/s10165-010-0310-x article EN Modern Rheumatology 2010-05-20

Autoantibody against platelet-derived growth factor receptors (PDGFRs) has been reported in scleroderma (SSc). However, it remains unknown whether anti-PDGFRs antibody exists collagen vascular diseases other than SSc. To answer the question, we developed an ELISA system and examined sera from patients with SLE (n = 75), SSc 31), RA 25) control individuals. We also reviewed medical records to clarify clinical features of anti-PDGFRα antibody. examine functions patients, fibroblasts were...

10.3109/s10165-010-0310-x article EN Modern Rheumatology 2010-10-01

Objectives: Trimethoprim–sulphamethoxazole (TMP–STX), an agent used for prophylaxis against pneumocystis pneumonia (PCP) in immunocompromised hosts, causes serious adverse effects (AEs) some patients. The objective of this study was to identify the risk factors AEs caused by TMP–STX connective tissue disease (CTD) patients and describe clinical features AEs. Methods: medical records 539 (CTDs 312, pulmonary diseases 227) receiving PCP were reviewed retrospectively. Patients with human...

10.3109/s10165-012-0625-x article EN Modern Rheumatology 2013-01-01

BTLA, a recently cloned coreceptor expressed on lymphocytes, negatively regulates cell activation by recruiting SHP-1/SHP-2. However, the mechanisms that regulate intracellular localization of BTLA and its trafficking to surface in T cells are still unknown. To determine expression cells, we examined subcellular mouse steady state, as well upon using confocal laser-scanning microscopy. We found was localized mainly Golgi apparatus secretory lysosomes resting CD4(+) cells. also translocated...

10.1189/jlb.0309138 article EN Journal of Leukocyte Biology 2009-11-05

A 26-year-old Japanese woman developed autoimmune pulmonary alveolar proteinosis (PAP) during glucocorticoid therapy for systemic lupus erythematosus (SLE). Intensive immunosuppressive worsened the PAP. De-escalation of improved Autoimmune PAP is rarely associated with diseases, and present case first SLE. Moreover, suggests that should be avoided or used carefully treatment patients anti-GM-CSF antibody, such as those

10.1177/0961203313498798 article EN Lupus 2013-07-25

Trimethoprim-sulphamethoxazole (TMP-STX), an agent used for prophylaxis against pneumocystis pneumonia (PCP) in immunocompromised hosts, causes serious adverse effects (AEs) some patients. The objective of this study was to identify the risk factors AEs caused by TMP-STX connective tissue disease (CTD) patients and describe clinical features AEs.The medical records 539 (CTDs 312, pulmonary diseases 227) receiving PCP were reviewed retrospectively. Patients with human immunodeficiency virus...

10.1007/s10165-012-0625-x article EN Modern Rheumatology 2012-03-30

Endogenous lipoid pneumonia is an uncommon inflammatory pulmonary disease that caused by lipids from endogenous source, the treatment for which has not been established. We report first case of presenting as lung consolidation and was associated with rheumatoid arthritis. Treatment successful intensive immunosuppressive therapy. When a physician finds in patient active rheumatic disease, should be considered.

10.1080/14397595.2016.1193270 article EN Modern Rheumatology 2016-06-20

Background: It is often difficult to differentiate between asthma and chronic obstructive pulmonary disease (COPD), useful biomarkers are needed for accurate diagnosis.Objective: We evaluated anti-elastin antibody identify differentiating a diagnosis of COPD.Method: Patients with (male female ratio = 10/13; mean age, 67.3 years), COPD (16/0; 74.8 years) controls (8/4; 72.3 were enrolled.Samples from sputum serum collected levels Ab measured. Results:The in significantly higher (11.4 ± 7.16...

10.12932/ap-010221-1052 article EN Asian Pacific Journal of Allergy and Immunology 2021-01-01

<h3>Background:</h3> Interstitial lung disease (ILD) is a serious organ involvement in rheumatoid arthritis (RA) that associated with poor prognosis and outcomes. Current evidence for the effects of biological DMARDs (bDMARDs) on RA-ILD has been conflicting. We previously reported switching from bDMARDs to targeted-synthetic (tsDMARDs) suppresses progression ILD CT as well activity patients RA (EULAR 2023). However, whether this inhibition tsDMARD-specific or via controlling unknown, few...

10.1136/annrheumdis-2024-eular.1604 article EN Annals of the Rheumatic Diseases 2024-06-01
Coming Soon ...